| Company Name: | Merck & Co Inc | | Ticker Symbol: | MRK | | | WWW Address: | www.merck.com |
| CEO: | Kenneth C. Frazier | | No. of Employees: | 83,000 |
| Common Issue Type: | CS | | Business Description: | Merck & Co Inc is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Major [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 47.33 |  0.62 | - | - | 46.46 | 47.44 | 46.42 | 22580823 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 142,918.2 | 3,019.6 | 0.60 | 2.00 | 1.69 | 24.3 | 3.6 | 48.79 - 37.02 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 47.33 | $ | | PE Ratio - LTM | 24.3 | |
| Market Capitalisation | 142,918.2 | mil |
| Latest Shares Outstanding | 3,019.6 | mil |
| Earnings pS (EPS) | 2.00 | $ |
| Dividend pS (DPS) | 1.69 | ¢ |
| Dividend Yield | 3.6 | % |
| Dividend Payout Ratio | 85 | % |
| Revenue per Employee | 569,482 | $ |
| Effective Tax Rate | 27.9 | % |
| Float | 3,016.4 | mil |
| Float as % of Shares Outstanding | 100.0 | % |
| Foreign Sales | 26,875 | mil |
| Domestic Sales | 20,392 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 27.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 17.80 | % |
| Gross Profit Margin | 79.4 | % |
| EBITDA Margin | 34.2 | % |
| Pre-Tax Profit Margin | 16.8 | % |
| Assets Turnover | 0.4 | % |
| Return on Assets (ROA) | 7.5 | % |
| Return on Equity (ROE) | 14.9 | % |
| Return on Capital Invested (ROCI) | 11.5 | % |
| Current Ratio | 1.9 | |
| Leverage Ratio (Assets/Equity) | 2.0 | |
| Interest Cover | 18.7 | |
| Total Debt/Equity (Gearing Ratio) | 0.39 | |
| LT Debt/Total Capital | 23.0 | % |
| Working Capital pS | 5.45 | $ |
| Cash pS | 4.31 | $ |
| Book-Value pS | 17.56 | $ |
| Tangible Book-Value pS | 4.21 | $ |
| Cash Flow pS | 4.89 | $ |
| Free Cash Flow pS | 0.98 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 2.70 | |
| Price/Tangible Book Ratio | 11.24 | |
| Price/Cash Flow | 9.7 | |
| Price/Free Cash Flow | 48.1 | |
| P/E as % of Industry Group | 92.0 | % |
| P/E as % of Sector Segment | 130.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 02/25/2013 |
| Dividend Ex-Date | 03/12/2013 |
| Dividend Record Date | 03/14/2013 |
| Dividend Pay Date | 04/04/2013 |
| Dividend Amount | 430 |
| Type of Payment | Cash Payment |
| Dividend Rate | 1.72 |
| Current Dividend Yield | 3.6 |
| 5-Y Average Dividend Yield | 4.4 |
| Payout Ratio | 85.0 |
| 5-Y Average Payout Ratio | 155.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 2.9 | 104 | 213,412 | 1,289,167 |
| 4 Weeks | 48.30 | 44.60 | 47.87 | -1.1 | 95 | 196,069 | 3,725,313 |
| 13 Weeks | 48.79 | 42.10 | 42.97 | 10.1 | 101 | 174,012 | 10,962,733 |
| 26 Weeks | 48.79 | 40.02 | 44.28 | 6.9 | 91 | 158,553 | 19,660,622 |
| 52 Weeks | 48.79 | 37.02 | 37.55 | 26.0 | 101 | 145,422 | 36,064,714 |
| YTD | 48.79 | 40.83 | - | 15.6 | 100 | 166,613 | 16,494,642 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 46.51 | 46.44 | 45.91 | 44.10 | 44.30 | 0.60 | 0.39 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 17.33 | 80.4 | 8.43 |
| Income | -12.84 | 6.6 | 4.34 |
| Dividend | 1.96 | 65.2 | 3.57 |
| Capital Spending | -4.55 | NA | -37.53 |
| R&D | 13.53 | NA | 4.06 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -9.0 | -9.0 | -1.6 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | -7.1 | -7.1 | -1.0 |
| EPS $ | -0.04 | -0.04 | -0.02 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 15.56 |
| Current Ratio | 1.9 |
| Quick Ratio (Acid Test) | 1.3 |
| Liquidity Ratio (Cash) | 0.88 |
| Receivables Turnover | 5.9 |
| Average Collection Period | 61 |
| Working Capital/Equity | 31.1 |
| Working Capital pS | 5.45 |
| Cash-Flow pS | 4.39 |
| Free Cash-Flow pS | 0.94 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.65 |
| Financial Leverage Ratio (Assets/Equity) | 2.0 |
| Debt Ratio | 50.0 |
| Total Debt/Equity (Gearing Ratio) | 0.39 |
| LT Debt/Equity | 0.31 |
| LT Debt/Capital Invested | 50.2 |
| LT Debt/Total Liabilities | 30.6 |
| Interest Cover | 13.2 |
| Interest/Capital Invested | 0.81 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 11.38 |
| Tobin's Q Ratio | 1.35 |
| Current P/E Ratio - LTM | 24.30 |
| Enterprise Value (EV)/EBITDA | 10.67 |
| Enterprise Value (EV)/Free Cash Flow | 61.46 |
| Dividend Yield | 3.6 |
| Price/Tangible Book Ratio - LTM | 11.24 |
| Price/Book Ratio - LTM | 2.70 |
| Price/Cash Flow Ratio | 9.7 |
| Price/Free Cash Flow Ratio - LTM | 48.1 |
| Price/Sales Ratio | 3.09 |
| P/E Ratio (1 month ago) - LTM | 24.9 |
| P/E Ratio (26 weeks ago) - LTM | 20.2 |
| P/E Ratio (52 weeks ago) - LTM | 16.7 |
| 5-Y High P/E Ratio | 148.4 |
| 5-Y Low P/E Ratio | 3.5 |
| 5-Y Average P/E Ratio | 36.5 |
| Current P/E Ratio as % of 5-Y Average P/E | 66 |
| P/E as % of Industry Group | 92.0 |
| P/E as % of Sector Segment | 130.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 22.3 |
| PER SHARE FIGURES |
| LT Debt pS | 5.37 |
| Current Liabilities pS | 6.06 |
| Tangible Book Value pS - LTM | 4.21 |
| Book Value pS - LTM | 17.56 |
| Capital Invested pS | 22.94 |
| Cash pS - LTM | 4.31 |
| Cash Flow pS - LTM | 4.89 |
| Free Cash Flow pS - LTM | 0.98 |
| Earnings pS (EPS) | 2.00 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 5.99 |
| Free Cash Flow Margin 5YEAR AVG | -0.35 |
| Net Profit Margin | 13.3 |
| Net Profit Margin - 5YEAR AVRG. | 7.3 |
| Equity Productivity | 0.89 |
| Return on Equity (ROE) | 11.9 |
| Return on Equity (ROE) - 5YEAR AVRG. | 5.9 |
| Capital Invested Productivity | 0.68 |
| Return on Capital Invested (ROCI) | 9.1 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 4.6 |
| Assets Productivity | 0.40 |
| Return on Assets (ROA) | 5.9 |
| Return on Assets (ROA) - 5YEAR AVRG. | 3.0 |
| Gross Profit Margin | 79.4 |
| Gross Profit Margin - 5YEAR AVRG. | 79.1 |
| EBITDA Margin - LTM | 34.2 |
| EBIT Margin - LTM | 18.0 |
| Pre-Tax Profit Margin | 18.5 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 22.3 |
| Effective Tax Rate | 27.9 |
| Effective Tax Rate - 5YEAR AVRG. | 23.3 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 301 |
| Revenue per Employee | 569,482 |
| Net Income per Employee | 75,892 |
| Average Collection Period | 58 |
| Receivables Turnover | 5.9 |
| Day's Inventory Turnover Ratio | 243 |
| Inventory Turnover | 1.5 |
| Inventory/Sales | 13.8 |
| Accounts Payble/Sales | 3.71 |
| Assets/Revenue | 2.50 |
| Net Working Capital Turnover | 2.86 |
| Fixed Assets Turnover | 0.66 |
| Total Assets Turnover | 0.4 |
| Revenue per $ Cash | 3.51 |
| Revenue per $ Plant | 2.95 |
| Revenue per $ Common Equity | 0.89 |
| Revenue per $ Capital Invested | 0.68 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 27.0 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 28.9 |
| Research & Devlopment (R&D) as % of Revenue | 17.3 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 17.3 |
|
|  
| | |  |  | |
| |
